Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Diagnostic radiopharmaceuticals | 1 |
Radiolabeled antibody | 1 |
Target- |
Mechanism Central nervous system stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Jan 2016 |
Target |
Mechanism H1 receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date28 Mar 2013 |
Target |
Mechanism Proton pump inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date14 Oct 1997 |
Start Date01 Sep 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator Aytu Biopharma, Inc. [+1] |
Start Date01 Oct 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Methylphenidate Hydrochloride ( DAT ) | Attention Deficit Disorder With Hyperactivity More | Approved |
Capromab Pendetide ( PSMA ) | Prostatic Cancer More | Approved |
Carbinoxamine Maleate ( H1 receptor ) | Urticaria More | Approved |
Amphetamine | Attention Deficit Disorder With Hyperactivity More | Approved |
Zolpidem Tartrate ( GABAA receptor ) | Sleep Initiation and Maintenance Disorders More | Approved |